Vioxx Cardiovascular Risk Is Unique To Molecule, Pfizer And Novartis Tell FDA
Executive Summary
The cardiovascular safety signal observed in Merck's Vioxx may be caused by the formation of potentially toxic rofecoxib metabolites, Pfizer states in its briefing documents for FDA's upcoming review of COX-2 inhibitors
You may also be interested in...
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
Bextra Use Suspended By Kaiser; Celebrex Alzheimer’s Data Under Scrutiny
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors